Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Nrf2/ARE pathway agonist omaveloxolone attenuates adverse cardiac remodeling in pressure-induced cardiac dysfunction.
Journal: Journal of cardiovascular pharmacology
Published: October 07, 2025
Omaveloxolone promotes macrophage M2 polarization by activating the NRF2-Keap1 pathway and improves myocardial remodeling induced by pressure overload.
Journal: Journal of cardiovascular pharmacology
Published: September 09, 2025
Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment.
Journal: International journal of molecular sciences
Published: September 05, 2025
Oxidative Stress and Antioxidant Therapies in Friedreich's Ataxia.
Journal: Cells
Published: July 31, 2025
Bidirectional regulation of KEAP1 BTB domain-based sensor activity.
Journal: Redox biology
Published: July 16, 2025
Leriglitazone improves iron homeostasis and ferroptotic markers in frataxin-deficient dorsal root ganglia neurons.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 08, 2025
Sensory nerve action potential reappearance after omaveloxolone treatment in patients with Friedreich ataxia.
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: July 01, 2025
The Central Role of NRF2 in Cancer Metabolism and Redox Signaling: Novel Insights into Crosstalk with ER Stress and Therapeutic Modulation.
Journal: Cell biochemistry and biophysics
Published: June 26, 2025
Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy.
Journal: Journal of the American Heart Association
Published: June 12, 2025
Characteristics of Adverse Events and Clinical Risks of Omaveloxolone Based on FAERS Data.
Journal: Cerebellum (London, England)
Published: June 10, 2025
Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons.
Journal: Antioxidants & redox signaling
Published: May 23, 2025
Last Updated: 10/31/2025